Drug Profile
NC 101
Alternative Names: NAIA 101; NC101Latest Information Update: 28 Apr 2019
Price :
$50
*
At a glance
- Originator Unknown
- Developer Naia Limited
- Class Antihyperglycaemics
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon-like peptide 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
- 28 Apr 2019 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 06 Apr 2017 Preclinical development for Non-alcoholic steatohepatitis and Type-2 diabetes mellitus is ongoing in USA (unspecified route) (Naia website, April 2017)